1.
Nat Rev Drug Discov
; 16(1): 1-2, 2017 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-27811930
RESUMEN
Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.